Company Profile
Veru Inc Stock Price, News & Analysis
- Ticker:
- VERU
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.31 USD (-0.86%)
Close
Last updated: August 6, 2026
37.7M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, VERU closed down 0.86% at $2.31. No new same-company headline was identified in the current news window.
Company overview
Cardiometabolic and Inflammation Company
Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases.
Enobosarm
Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity.
PLATEAU Study
The Phase 2b PLATEAU study combines enobosarm with semaglutide and measures body composition, weight, function, and safety.
Future catalysts
A PLATEAU interim analysis of lean and fat mass at 36 weeks is expected in the first quarter of 2027.
Final topline PLATEAU data are expected in the fourth quarter of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Veru Inc (VERU)?
Veru Inc (VERU) most recently closed at 2.31 USD, a -0.86% move versus the previous session.
What is the market cap of Veru Inc (VERU)?
Veru Inc currently has a market capitalization of 37.7M USD on BioPharmSignal.
What does Veru Inc do?
Cardiometabolic and Inflammation Company Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases. Enobosarm Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity. PLATEAU Study The Phase...
On which exchange is VERU stock listed?
Veru Inc (VERU) is associated with NASDAQ, United States, Biopharma.
What is GLP-1?
Enobosarm Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with obesity.
Which conditions is Veru Inc targeting with GLP-1?
Veru Inc is associated with inflammatory disease, metabolic disease, obesity based on its company overview and current catalyst commentary.
How does Veru Inc describe recent progress with GLP-1?
A PLATEAU interim analysis of lean and fat mass at 36 weeks is expected in the first quarter of 2027. Final topline PLATEAU data are expected in the fourth quarter of 2027.
What is semaglutide?
PLATEAU Study The Phase 2b PLATEAU study combines enobosarm with semaglutide and measures body composition, weight, function, and safety.